Samsky MD, Mentz RJ, Stebbins A, et al. - Type 2 diabetes (T2D) patients showed an incremental increase in the risk of major adverse cardiovascular events (MACE) and all-cause mortality (ACM) with each additional diseased arterial bed, compared with those without atherosclerotic vascular disease.

• This is a study from the Exenatide Study of Cardiovascular Event Lowering trial (EXSCEL) in which 14,751 participants were involved; 26.5% were without atherosclerosis, 1-diseased arterial bed, 2-bed, and 3-bed disease was evident in 58.9%, 12.3%, and 2.3%, respectively.

• In relation to increasing burden of atherosclerotic disease, an increasing risk of MACE (adjusted HR 1.71; 2.61; 3.46 for 1, 2, and 3 beds, respectively) and ACM (1.94; 3.03; 3.66 for 1, 2, and 3 beds, respectively) was observed among participants.

• No significant associations were found via prespecified interaction testing.